Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific demethylase 4A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.2696 | 0.1313 |
Brugia malayi | jmjC domain containing protein | 0.0043 | 0.2696 | 0.2696 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0043 | 0.2696 | 0.0925 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4588 | 0.4653 |
Brugia malayi | Bromodomain containing protein | 0.0035 | 0.1951 | 0.1951 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4588 | 0.4653 |
Plasmodium falciparum | phd finger protein, putative | 0.0035 | 0.1951 | 1 |
Brugia malayi | RNA binding protein | 0.0061 | 0.4588 | 0.4588 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0115 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4588 | 0.4653 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 0.4588 | 0.7669 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0073 | 0.5718 | 1 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0035 | 0.1951 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 0.4588 | 0.3276 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0035 | 0.1951 | 0.2229 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 0.4588 | 0.7669 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 0.4588 | 0.3276 |
Plasmodium vivax | hypothetical protein, conserved | 0.0035 | 0.1951 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4588 | 0.4653 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.4479 | 0.7443 |
Brugia malayi | PHD-finger family protein | 0.0035 | 0.1951 | 0.1951 |
Brugia malayi | TAR-binding protein | 0.0061 | 0.4588 | 0.4588 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0035 | 0.1951 | 1 |
Onchocerca volvulus | Alhambra homolog | 0.0035 | 0.1951 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0024 | 0.0871 | 0.5 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0043 | 0.2696 | 0.3765 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.2696 | 0.1313 |
Echinococcus granulosus | jumonji domain containing protein | 0.0049 | 0.3337 | 0.1721 |
Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.1951 | 0.2229 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0024 | 0.0871 | 0.5 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0043 | 0.2696 | 0.0925 |
Brugia malayi | hypothetical protein | 0.0024 | 0.0871 | 0.0871 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 0.4588 | 0.7669 |
Giardia lamblia | PHD finger protein 15 | 0.0035 | 0.1951 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 0.4588 | 0.4588 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0024 | 0.0871 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0115 | 1 | 1 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0049 | 0.3337 | 0.1721 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0024 | 0.0871 | 0.5 |
Schistosoma mansoni | jumonji domain containing protein | 0.0092 | 0.7619 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4588 | 0.4653 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.5119 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 30.1313 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.